Eliminating COVID-19 disparities in partnership with underserved/vulnerable transnational communities of Arizona
Project Number3U54MD002316-15S2
Former NumberU54MD002316-14S2
Contact PI/Project LeaderMARSIGLIA, FLAVIO FRANCISCO
Awardee OrganizationARIZONA STATE UNIVERSITY-TEMPE CAMPUS
Description
Abstract Text
Project Summary/Abstract
The COVID-19 pandemic significantly affects the entire State of Arizona but impacts communities along the
border with Mexico disproportionally. Majority Latinx and American Indian communities along this border have
higher infection rates and less access to testing and vaccination. This proposed supplement aims to increase
access to testing and related services for these underserved transnational communities. The expansion of our
current community-driven and culturally congruent project will advance knowledge about barriers to care and
effective strategies to increase testing and vaccination in the border region. This application extends the work
of ASU’s health disparities U54 center grant (RFA-MD-17-005; 5U54MD002316) and its RADx-UP supplement
(3U54MD002316-14S1) by reducing disparities in COVID-19 diagnostics, vaccination, education, wraparound
services and health care, with the goal of improving the health of vulnerable and underserved communities.
The aims of this emergency competitive revision closely match and enhance the aims of the current U54 award
and its RADx-UP supplement. The focus on populations along the AZ-Mexico border will add to existing
knowledge about assets and vulnerabilities of diverse transnational communities disproportionally affected by
the pandemic. The approach empowers local communities, is data driven, and creates the infrastructure
capacity for community-driven delivery of care. Following a Community Based Participatory Research (CBPR)
orientation, the revised supplement expands our existing R.A.P.I.D. program by improving access and
decreasing hesitancy to COVID-19 testing and vaccination among underserved and vulnerable populations in
the border region. Equality Health Foundation (EHF) will continue to serve as the lead community partner for
the proposed revised supplement and the ASU Biodesign Clinical Testing Laboratory (ABCTL) will provide and
analyze the saliva-based polymerase chain reaction (PCR) testing for SARS-CoV-2. Local partners
coordinated by EHF under the One Community Initiative against COVID-19 will implement the vaccination
program. Over two years, the revised supplement aims to reach 7,000 additional community members living
and working along the AZ-Mexico border. CDCC surveys from border communities will be added to the
ongoing longitudinal study we are conducting to assess the intervention’s impact and also by comparing
randomly selected participants (N=200) with a matched comparison group (N=200) randomly selected from
regular testing sites. We will also conduct ongoing COVID-19 variants sequence validation among those tested
and inform appropriate health authorities if significant variants emerge. The transdisciplinary team has the
infrastructure, capacity, and community partnerships in place to implement the project effectively and
efficiently. ASU’s existing NIMHD-funded U54 center, guided by its Community and Scientific Advisory Board
and in collaboration with government agencies, tribal governments, community organizations, and academic
units within ASU, is well equipped to undertake the proposed revised supplement.
Public Health Relevance Statement
Public Health Impact Statement
Findings from this competitive revision will inform public health approaches on how to make COVID-19 testing
more readily available to farm workers and other vulnerable and underserved communities living and working
along the AZ-Mexico border region. The proposed revision will advance knowledge about SDoH and will
develop and test strategies on how to overcome existing barriers to care. This application is relevant for
NIH/NIMHD’s mission to fostering fundamental creative discoveries and innovative research strategies as a
basis for advancing health equity and protecting health.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AddressAffectAmerican IndiansArizonaAwardBehaviorBorder CommunityCOVID-19COVID-19 diagnosticCOVID-19 disparityCOVID-19 pandemicCOVID-19 testingCOVID-19 vaccinationCOVID-19 vaccineCaringCitiesCollaborationsCommunitiesCommunity Health AidesConsentConsultationsDataDiagnosticEducationEffectiveness of InterventionsEmergency SituationEnsureEvolutionFosteringFoundationsFundingGoalsGovernmentGovernment AgenciesGrantHealthHealth Knowledge, Attitudes, PracticeHealth educationHealthcareImmunization ProgramsImprove AccessInfrastructureInterventionKnowledgeLaboratoriesLatinxLeadLongitudinal StudiesMedicalMexicanMexicoMigrantMissionModelingMonitorNeighborhood Health CenterParticipantPatientsPersonal SatisfactionPhasePolymerase Chain ReactionPopulationProtocols documentationProviderPublic HealthRADx Underserved PopulationsResearchSARS-CoV-2 variantSalivaSample SizeSamplingScheduleScholarshipServicesSiteSurveysTest ResultTestingTimeUnderserved PopulationUnited States National Institutes of HealthVaccinationVaccinesValidationVariantVulnerable PopulationsWorkauthoritybarrier to carebasecare deliverycommunity based participatory researchcommunity livingcommunity organizationscommunity partnershipcomparison groupcomparison interventiondisparity reductionexperiencefarm workerfollow-uphealth disparityhealth equalityhealth equityimprovedinfection rateinnovationliteracymemberpandemic diseasepreventprogramsresearch clinical testingsalivary assaysocial disadvantagesocial health determinantstesting servicesunderserved communityuptakevaccine acceptancevaccine hesitancy
National Institute on Minority Health and Health Disparities
CFDA Code
310
DUNS Number
943360412
UEI
NTLHJXM55KZ6
Project Start Date
30-September-2007
Project End Date
30-June-2025
Budget Start Date
01-September-2021
Budget End Date
30-June-2025
Project Funding Information for 2021
Total Funding
$996,702
Direct Costs
$749,464
Indirect Costs
$247,238
Year
Funding IC
FY Total Cost by IC
2021
NIH Office of the Director
$996,702
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3U54MD002316-15S2
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3U54MD002316-15S2
Patents
No Patents information available for 3U54MD002316-15S2
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3U54MD002316-15S2
Clinical Studies
No Clinical Studies information available for 3U54MD002316-15S2
News and More
Related News Releases
No news release information available for 3U54MD002316-15S2
History
No Historical information available for 3U54MD002316-15S2
Similar Projects
No Similar Projects information available for 3U54MD002316-15S2